Ellen A. Cannady
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms, Lipoproteins and Cardiovascular Health, Reproductive Biology and Fertility, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure(2011)115 cited
- → Expression and Activity of Cytochromes P450 2E1, 2A, and 2B in the Mouse Ovary: The Effect of 4-Vinylcyclohexene and Its Diepoxide Metabolite(2003)62 cited
- → Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib(2017)60 cited
- → Expression and Activity of Microsomal Epoxide Hydrolase in Follicles Isolated from Mouse Ovaries(2002)58 cited
- → The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)(2016)58 cited
- → Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia(2015)57 cited
- → Involvement of CYP 2E1 enzyme in ovotoxicity caused by 4-vinylcyclohexene and its metabolites(2007)40 cited
- → Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults(2014)35 cited
- → Discovery of potent small-molecule inhibitors of lipoprotein(a) formation(2024)30 cited
- → Design, synthesis and structure–activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors(2012)28 cited